PP_1170x120_10-25-21

Braftovi (encorafenib and Mektovi (binimetinib)

Avella to distribute Braftovi and Mektovi

Avella to distribute Braftovi and Mektovi

PHOENIX —  Avella has announced that it will distribute Braftovi (encorafenib and Mektovi (binimetinib), a combination therapy recently FDA approved for patients for the treatment of patients with unresectable or metastatic melanoma. Metastatic melanoma is the most serious, life-threatening type of skin cancer and is associated with low survival rates overall. Approximately 9,000 people are expected to die of melanoma in 2018. There